Morgan Stanley Maintains Underweight on Genmab, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Underweight rating on Genmab (NASDAQ:GMAB) and lowers the price target from $33 to $32.
November 09, 2023 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Underweight rating on Genmab and lowered the price target from $33 to $32.
The lowered price target by Morgan Stanley indicates a bearish outlook for Genmab. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100